Sign In
Buy MNKD
$4.13
+0.240 (+6.17%)
At Close: Jul 24, 2026
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
07:10am, Wednesday, 06'th Aug 2025
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
07:05am, Wednesday, 06'th Aug 2025
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v.
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
04:05pm, Wednesday, 30'th Jul 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for
11:07am, Wednesday, 30'th Jul 2025
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
09:15am, Tuesday, 27'th May 2025
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a on
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
12:02am, Tuesday, 27'th May 2025
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, suppor
MannKind to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 13'th May 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled the
MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
11:34am, Thursday, 08'th May 2025
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
10:25am, Thursday, 08'th May 2025
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
08:05am, Thursday, 08'th May 2025
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
04:05pm, Thursday, 01'st May 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WE
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
10:32am, Thursday, 27'th Feb 2025
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential
